Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

ABSTRACT: The advent of targeted therapies has established new standards of care for defined molecular subsets of non-small cell lung cancer (NSCLC). Not only has this led to significant changes in the routine clinical management of lung cancer e.g., multiplexed genomic testing, but it has provided important principles and benchmarks for determining "actionability". At present, the clinical paradigms are most evolved for EGFR mutations and ALK rearrangements, where multiple randomized phase III trials have determined optimal treatment strategies in both treatment naïve and resistant settings. However, this may not always be feasible with low prevalence alterations e.g., ROS1 and BRAF mutations. Another emerging observation is that not all targets are equally "actionable", necessitating a rigorous pr

SUBMITTER: Lau KW 

PROVIDER: S-EPMC5635263 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature